Bone Health and Renal Replacement Therapies: Which are the Best?

BMD level was lowest in group 1 and similar in groups 2-3, groups 2 and 4 and groups 3-4. conclusion: This study showed that renal transplantation is the most effective and safe renal replacement therapy modality in terms of bone health α-Klotho gene polymorphism, FGF-23 levels, indicators of bone metabolism and bone mineral density for end-stage renal disease patients

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Objective: The aim of this study was to evaluate the efficacy and safety of renal replacement therapy modalities in terms of bone health for end-stage renal disease patients.Material and Methods: We included 27 hemodialysis group 1 , 51 chronic peritoneal dialysis group 2 , and 25 renal transplant patients group 3 and 40 healthy subjects control, group 4 in the study.

📊

Key Findings & Data:Intact parathormone iPTH , fibroblast growth factor 23 FGF-23 , osteoprotogerin OPG , osteocalcin OC , procollagen type-1 N terminal propeptide PINP , beta- crosslaps beta CTx , tartarate resistant acid phosphatase TRAP5b , bone alkaline phosphatase BAP , 1,25 OH D3 and 25 OH D3 levels were measured in the patients and the control group.

💡

Conclusion & Impact:BMD level was lowest in group 1 and similar in groups 2-3, groups 2 and 4 and groups 3-4. conclusion: This study showed that renal transplantation is the most effective and safe renal replacement therapy modality in terms of bone health α-Klotho gene polymorphism, FGF-23 levels, indicators of bone metabolism and bone mineral density for end-stage renal disease patients

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Periton diyalizi · Hemodiyaliz · Böbrek nakli

Abstract

Objective: The aim of this study was to evaluate the efficacy and safety of renal replacement therapy modalities in terms of bone health for end-stage renal disease patients.Material and Methods: We included 27 hemodialysis group 1 , 51 chronic peritoneal dialysis group 2 , and 25 renal transplant patients group 3 and 40 healthy subjects control, group 4 in the study. Intact parathormone iPTH , fibroblast growth factor 23 FGF-23 , osteoprotogerin OPG , osteocalcin OC , procollagen type-1 N terminal propeptide PINP , beta- crosslaps beta CTx , tartarate resistant acid phosphatase TRAP5b , bone alkaline phosphatase BAP , 1,25 OH D3 and 25 OH D3 levels were measured in the patients and the control group. The α-Klotho gen mutation F352V was evaluated by real-time PCR and the high-resolution melting method.results: The α-Klotho gene polymorphism rates wild/heterozygote/mutation: 22 81.5% / 0 0% / 5 18.5% and FGF23 levels G1-2-3-4 1252±310 / 872±526 / 34.6 / 82 respectively were significantly higher in group 1. The 1.25 OH D3 and 25 OH D3 levels were lower in groups 1 and 2 but similar in group 3 and 4. The iPTH, FGF-23, OPG, OC and TRAP5b levels were significantly higher in Group 1 and 2. The PINP and beta CTx levels were highest in group 1. BMD level was lowest in group 1 and similar in groups 2-3, groups 2 and 4 and groups 3-4. conclusion: This study showed that renal transplantation is the most effective and safe renal replacement therapy modality in terms of bone health α-Klotho gene polymorphism, FGF-23 levels, indicators of bone metabolism and bone mineral density for end-stage renal disease patients

Özet

Amaç: Çalışmada, son dönem böbrek yetmezliği hastalarında renal replasman tedavilerinin kemik sağlığı açısından etkinlik ve güvenilirliklerinin değerlendirilmesi amaçlanmıştır. Gereç ve Yöntemler: Çalışmaya 27 hemodiyaliz HD, Grup 1 , 51 periton diyalizi PD, Grup 2 , 25 böbrek nakli Rtx, Grup 3 hastası ve 40 sağlıklı kontrol grubu Grup 4 alındı. Hastalar ve kontrol grubunun intakt parathormon iPTH , fibroblast growth faktor 23 FGF-23 , osteoprotogerin OPG , osteokalsin OK , prokollagen tip-1 N terminal propeptid PINP , beta- crosslaps beta CTx , tartarat rezistan asid fosfataz TRAF5b , kemik alkalen fosfataz KAF , 1,25 OH D3 ve 25 OH D3 düzeyleri ölçüldü. α-Klotho gen mutasyonu F352V gerçek zaman PCR ve yüksek çözünürlüklü erime yöntemi kullanılarak değerlendirildi. Bulgular: α- klotho gen polimorfizmi wild/heterezigot/mutasyon: 22 %81,5 / 0 %0 / 5 %18,5 ve FGF23 düzeylerinin G1-2-3-4 sırayla; 1252±310/ 872±526/ 34,6 1,3-986 / 82 23-991 HD hastalarında diğer tüm gruplardan anlamlı derecede daha yüksek olduğu görüldü. 1,25 OH D3 ve 25 OH D3 düzeylerinin HD ve PD hastalarında diğer gruplardan daha düşük, G3-G4 arasında benzer olduğu görüldü. iPTH, FGF-23, OPG, OC ve TRAP5b düzeylerinin G1 ve G2 hastalarında diğer gruplardan daha yüksek, PINP ve beta CTx düzeylerinin G1’de en yüksek, kemik mineral yoğunluğu KMY ise G1’de en düşük iken G2-G3, G2-G4 ve G3-G4 arasında benzer olduğu görüldü. Sonuç: Çalışmamızda böbrek naklinin; son dönem böbrek yetmezliği hastaları için kemik sağlığı αklotho gen polimorfizmi, FGF23 düzeyleri, kemik metabolizma markırları ve kemik mineral yoğunluğu açısından en etkin ve güvenilir renal replasman tedavisi olduğu gösterilmiştir

Keywords

Periton diyalizi Hemodiyaliz Böbrek nakli FGF-23 α- klotho gen polimorfizmi Kemik mineral yoğunluğu Peritoneal dialysis Hemodialysis Renal transplantation α-Klotho gene polymorphism Bone mineral density

🔖

Cite This Article

DÖNMEZ, L., YILMAZ, V. T., ÖZDEM, S., ÇETİNKAYA, R., SÜLEYMANLAR, G., ERSOY, F. F. (2022). Bone Health and Renal Replacement Therapies: Which are the Best?. Akdeniz Tıp Dergisi, Cilt: 1 - Sayı: 1, 25–42. https://ajindex.com/articles/648393

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (13)

Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359:584-92
Seiler S, Heine GH, Fliser D. Clinical relevance of FGF-23 in chronic kidney disease.Kidney Int Suppl 2009;114:S34- 42
Damasiewicz MJ, Toussaint ND, Polkinghorne KR. Fibroblast growth factor 23 in chronic kidney disease: New insights and clinical implications. Nephrology (Carlton) 2011;16:261-8
Gutiérrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M. Fibroblast Growth Factor-23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009;119:2545-52
Jongbloed F, Galassi A, Cozzolino M, Zietse R, Chiarelli G, Cusi D, Brancaccio D, Gallieni M. Clinical significance of FGF-23 measurement in dialysis patients. Clin Nephrol 2011;76:201-9
Huang CL. Regulation of ion channels by secreted Klotho: Mechanisms and implications. Kidney Int 2010;77:855-60
Cozzolino M, Galassi A, Apetrii M, Covic A. What would we like to know, and what do we not know about fibroblast growth factor 23. J Nephrol 2011;24:696-706
Choi BH, Kim CG, Lim Y, Lee YH, Shin SY. Transcriptional activation of the human Klotho gene by epidermal growth factor in HEK293 cells; role of Egr-1. Gene 2010;450:121- 7
Adijiang A, Niwa T. An oral sorbent, AST-120, increases Klotho expression and inhibits cell senescence in the kidney of uremic rats. Am J Nephrol 2010;31:160-4
Torres PU, Prié D, Molina-Blétry V, Beck L, Silve C, Friedlander G. Klotho: An antiaging protein involved in mineral and vitamin D metabolism. Kidney Int 2007;71:730- 7
Bostrom MA, Hicks PJ, Lu L, Langefeld CD, Freedman BI, Bowden DW. Association of polymorphisms in the klotho gene with severity of non-diabetic ESRD in African Americans. Nephrol Dial Transplant 2010;25:3348-55
Oguro R, Kamide K, Kokubo Y, Shimaoka I, Congrains A, Horio T, Hanada H, Ohishi M, Katsuya T, Okamura T, Miyata T, Kawano Y, Rakugi H. Association of carotid atherosclerosis with genetic polymorphisms of the klotho gene in patients with hypertension. Geriatr Gerontol Int 2010;10:311-8
Shimoyama Y, Taki K, Mitsuda Y, Tsuruta Y, Hamajima N, Niwa T. KLOTHO gene polymorphisms G-395A and C1818T are associated with low-density lipoprotein cholesterol and uric acid in Japanese hemodia